Ann Lee - 03 Jan 2022 Form 4 Insider Report for Coya Therapeutics, Inc. (COYA)

Role: Director
Signature: /s/ David Snyder, Attorney-in-Fact
Issuer symbol: COYA
Transactions as of: 03 Jan 2022
Net transactions value: +$916
Form type: 4
Filing time: 04 Jan 2023, 07:30:27 UTC
Next filing: 28 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	COYA	Common Stock, par value $0.0001 per share	Purchase		+10,000			10,000	03 Jan 2023	Direct	F1
transaction	COYA	Common Stock, par value $0.0001 per share	Conversion of derivative security	$25,916	+6,479	+65%	$4.00	16,479	03 Jan 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	COYA	Warrant to Purchase Common Stock	Purchase		+5,000	+112%		9,479	03 Jan 2023	Common Stock, par value $0.0001 per share	5,000	$7.50	Direct	F1
transaction	COYA	6% Convertible Note	Conversion of derivative security	$25,000				6,479	03 Jan 2023	Common Stock, par value $0.0001 per share	6,479	$4.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reporting Person purchased 10,000 shares of Common Stock and accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering ("IPO") at a combined purchase price $5.00 per share and accompanying warrant.
F2	Upon the closing of the Issuer's IPO, the Convertible Note automatically converted into shares of common stock by dividing the then-outstanding principal and interest due under the Convertible Note by $4.00, or 80% of the IPO price. The Reporting Person held a Convertible Note for $25,000 that accrued interest at 6% per annum.